RELMADA THERAPEUTICS INC (RLMD) Stock Price, Quote, News and Overview
NASDAQ:RLMD - Nasdaq - US75955J4022 - Common Stock - Currency: USD
RLMD Quote, Performance and Key Statistics
0.3983
-0.02 (-5.05%)
The current stock price of RLMD is 0.3983 USD. In the past month the price increased by 34.79%. In the past year, price decreased by -88.07%.
RLMD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 54.91 | 716.27B | ||
| JNJ | JOHNSON & JOHNSON | 15.34 | 370.87B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.75 | 300.70B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.11 | 215.19B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.53 | 213.77B | ||
| MRK | MERCK & CO. INC. | 10.32 | 202.39B | ||
| PFE | PFIZER INC | 7.19 | 130.95B | ||
| SNY | SANOFI-ADR | 13.58 | 125.00B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.56 | 98.05B | ||
| GSK | GSK PLC-SPON ADR | 6.91 | 75.61B | ||
| ZTS | ZOETIS INC | 26.9 | 72.23B | ||
| HLN | HALEON PLC-ADR | 22.31 | 48.29B |
Related stock screener links
About RLMD
Company Profile
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. The company is headquartered in Coral Gables, Florida and currently employs 17 full-time employees. The company went IPO on 2014-03-03. The firm is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.
Company Info
RELMADA THERAPEUTICS INC
2222 Ponce De Leon Blvd. 3Rd Floor
Coral Gables FLORIDA 10022 US
CEO: Sergio Traversa
Employees: 17
Phone: 16468763459
RELMADA THERAPEUTICS INC / RLMD FAQ
What is the stock price of RELMADA THERAPEUTICS INC today?
The current stock price of RLMD is 0.3983 USD. The price decreased by -5.05% in the last trading session.
What is the ticker symbol for RELMADA THERAPEUTICS INC stock?
The exchange symbol of RELMADA THERAPEUTICS INC is RLMD and it is listed on the Nasdaq exchange.
On which exchange is RLMD stock listed?
RLMD stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for RELMADA THERAPEUTICS INC stock?
8 analysts have analysed RLMD and the average price target is 0.88 USD. This implies a price increase of 121.95% is expected in the next year compared to the current price of 0.3983. Check the RELMADA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is RELMADA THERAPEUTICS INC worth?
RELMADA THERAPEUTICS INC (RLMD) has a market capitalization of 13.22M USD. This makes RLMD a Nano Cap stock.
How many employees does RELMADA THERAPEUTICS INC have?
RELMADA THERAPEUTICS INC (RLMD) currently has 17 employees.
What are the support and resistance levels for RELMADA THERAPEUTICS INC (RLMD) stock?
RELMADA THERAPEUTICS INC (RLMD) has a support level at 0.3 and a resistance level at 0.42. Check the full technical report for a detailed analysis of RLMD support and resistance levels.
Should I buy RELMADA THERAPEUTICS INC (RLMD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RLMD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RLMD, evaluating the profitability, health, valuation and growth aspects
- RELMADA THERAPEUTICS INC (RLMD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- RELMADA THERAPEUTICS INC (RLMD) Sales and EPS estimates to see what analysts future expectations are.
- RELMADA THERAPEUTICS INC (RLMD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- RELMADA THERAPEUTICS INC (RLMD) Insider and Institutional Ownership to learn about the owners and their transactions.
- RELMADA THERAPEUTICS INC (RLMD) Stock Chart to make your own analysis
- RELMADA THERAPEUTICS INC (RLMD) Latest news and press-releases to stay up to date.
Does RELMADA THERAPEUTICS INC (RLMD) stock pay dividends?
RLMD does not pay a dividend.
When does RELMADA THERAPEUTICS INC (RLMD) report earnings?
RELMADA THERAPEUTICS INC (RLMD) will report earnings on 2025-08-05.
What is the Price/Earnings (PE) ratio of RELMADA THERAPEUTICS INC (RLMD)?
RELMADA THERAPEUTICS INC (RLMD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.51).
What is the Short Interest ratio of RELMADA THERAPEUTICS INC (RLMD) stock?
The outstanding short interest for RELMADA THERAPEUTICS INC (RLMD) is 7.39% of its float. Check the ownership tab for more information on the RLMD short interest.
RLMD Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to RLMD. When comparing the yearly performance of all stocks, RLMD is a bad performer in the overall market: 88.49% of all stocks are doing better.
RLMD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RLMD. RLMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
RLMD Financial Highlights
Over the last trailing twelve months RLMD reported a non-GAAP Earnings per Share(EPS) of -2.51. The EPS increased by 19.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -174.56% | ||
| ROE | -225.15% | ||
| Debt/Equity | 0 |
RLMD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 48% to RLMD. The Buy consensus is the average rating of analysts ratings from 8 analysts.